Study Design
We performed a randomized double-blind, placebo controlled study of
benralizumab in patients with severe CRSwNP refractory to standard
treatment, that minimally included the use of nasal steroids and at
least one prior polypectomy. Subjects were instructed to abstain from
taking oral or nasal corticosteroids and antihistamines for a period of
one month before screening. Subjects meeting criteria for entry were
randomized to receive benralizumab 30mg SC or placebo according to the
schedule illustrated in Figure 1. During the study, subjects with
inadequate control of symptoms were offered nasal steroids and/or oral
corticosteroids according to a predetermined rescue protocol.